| Microorganism |  |  |  | 
  
    | Antimicrobial |  |  | Reference | 
            
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.015 | 0.03 | 0.015 - 0.03 | AC98-6446  | 175 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.015 | 0.5 | ≤0.004 - 4 | Gemifloxacin  | 268 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.03 | 0.06 | ≤0.015 - 0.06 | Dalbavancin  | 72 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.03 | 0.12 | ≤0.03 - 0.5 | Imipenem  | 371 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.03 | 0.5 | ≤0.016 - 2 | Moxifloxacin (BAY 12-8039, Avelox)  | 207 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.03 | 0.5 | 0.12 - 1 | DC-159a  | 268 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.03 | 1 | 0.015 - 8 | Garenoxacin (T-3811, BMS-284756)  | 268 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | ≤0.06 | ≤0.06 | ≤0.06 - >16 | Gentamicin (Gentamycin, Garamycin)  | 73 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.06 | 0.12 | 0.008 - 1 | Imipenem  | 102 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.06 | 0.12 | 0.015 - 4 | Garenoxacin (T-3811, BMS-284756)  | 102 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.06 | 0.12 | 0.03 - >128 | Telithromycin (HMR 3647, RU-66647, Ketek)  | 162 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.06 | 0.25 | ≤0.06 - 0.5 | TAK-599  | 162 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.06 | 0.5 | ≤0.03 - >8 | Telithromycin (HMR 3647, RU-66647, Ketek)  | 73 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.06 | 1 | 0.03 - 4 | Gatifloxacin (Tequin)  | 207 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.06 | 1 | 0.03 - 8 | Moxifloxacin (BAY 12-8039, Avelox)  | 268 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.12 | 0.12 | ≤0.06 - 0.25 | Oxacillin (Prostaphilin, Bactocil, Prostaphlin)  | 73 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | ≤0.12 | ≤0.12 | ≤0.12 - 0.25 | Gentamicin (Gentamycin, Garamycin)  | 89 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.12 | 0.25 | 0.06 - 0.25 | Levofloxacin (Levaquin, Quixin)  | 16 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.12 | 0.25 | 0.06 - 0.5 | Daptomycin (Cubicin)  | 16 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.12 | 0.25 | 0.06 - 4 | Moxifloxacin (BAY 12-8039, Avelox)  | 102 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.12 | 0.25 | 0.06 - 8 | Sparfloxacin (AT-4140, Zagam)  | 117 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.12 | 0.25 | ≤0.12 - 0.25 | Quinupristin/Dalfopristin (Synercid)  | 73 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.12 | 0.25 | ≤0.12 - >64 | Clindamycin (Cleocin)  | 371 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.12 | 0.5 | ≤0.06 - 1 | Ranbezolid (RBX 7644)  | 162 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.12 | 8 | ≤0.12 - >64 | Erythromycin (E-mycin, Ery-tab, Benzamycin)  | 371 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.123 | 0.625 | ? - ? | Ceftobiprole (Zeftera)  | 942 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.125 | 0.5 | ≤0.06 - 1 | Quinupristin/Dalfopristin (Synercid)  | 207 | 
                
			        
			            | Staphylococci (coagulase-negative + methicillin-susceptible) | 0.125 | 0.5 | ≤0.06 - 1 | Quinupristin/Dalfopristin (Synercid)  | 72 |